Bayer puts the brakes on vilaprisan trials following safety concerns
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
Esmya rejection hits Allergan's streamlining
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
First-quarter floats see haves pulling away from the have-nots
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.